Optimizing Emergency Care: The Prospective Role Of Antibiotic Stewardship In Shaping Biochemical Markers And Combating Microbial Resistance At A Tertiary Care Hospital In Central India

Dr. Kanupriya Tiwari[1], Dr. Kuldeep Singh[2], Dr. Rajdeep Paul[3], Dr. Namrata Naithani[4*]

[1]Senior Resident, Postgraduate Department of Clinical Microbiology, King George's Medical University

[2]Assistant Professor, Department of Microbiology, Chirayu Medical College & Hospital, Bhopal, M.P.

[3]Assistant Professor, Department of Microbiology, Chirayu Medical College & Hospital, Bhopal, M.P.

[4*]Assistant Professor, Department of Microbiology, Chirayu Medical College & Hospital, Bhopal, M.P.

***Corresponding Author:** Dr. Namrata Naithani

*Assistant Professor, Department of Microbiology, Chirayu Medical College & Hospital, Bhopal, M.P., namratanaithani2211@gmail.com

Abstract

Antibiotic stewardship programs (ASPs) play a crucial role in optimizing antibiotic use and combating microbial resistance, particularly in emergency care settings. This prospective study, conducted at a tertiary care hospital in Central India, aimed to evaluate the impact of ASPs on various clinical outcomes, including biochemical markers, microbial resistance patterns, and overall infection management. Over a 12-month period, the study compared infection-related data from patients before and after the implementation of an ASP. Key biochemical markers, such as C-reactive protein (CRP) and procalcitonin (PCT), were assessed to determine changes in inflammation and infection severity. Microbial cultures were analyzed to evaluate shifts in resistance rates among common pathogens. Additionally, antibiotic usage patterns were monitored to identify changes in prescribing practices, while the length of hospital stay was evaluated to assess overall patient outcomes.

The results indicated a significant reduction in CRP and PCT levels post-ASP implementation, suggesting improved infection control and more targeted antibiotic therapy. Notable decreases in resistance rates for pathogens such as *Escherichia coli* and *Staphylococcus aureus* were observed, reflecting the successful impact of ASPs on reducing microbial resistance. Changes in antibiotic usage patterns showed a decrease in the use of broad-spectrum antibiotics, including cephalosporins and fluoroquinolones, in favor of more appropriate antibiotic choices. Furthermore, the average length of hospital stay was significantly reduced, highlighting the efficiency gains associated with ASPs.

These findings underscore the effectiveness of ASPs in optimizing emergency care by improving infection management, reducing resistance rates, and promoting more judicious use of antibiotics. The study's results are consistent with recent literature, reinforcing the value of ASPs in various healthcare settings. The research supports the continued investment in and evaluation of ASPs to address the growing challenge of antibiotic resistance and enhance patient outcomes. Future studies should focus on validating these findings in broader settings and exploring the long-term effects of ASPs on resistance patterns, patient outcomes, and economic implications.

Introduction

Antibiotic resistance represents a major challenge in emergency medicine, especially in resource-limited settings where timely and effective treatment is crucial. Antibiotic stewardship programs (ASPs) are designed to promote the appropriate use of antibiotics and combat resistance through structured strategies, including prescribing guidelines, provider education, and monitoring of antibiotic use [1][2]. This study focuses on a tertiary care hospital in Central India and evaluates the impact of ASPs on biochemical markers, resistance patterns, and overall infection management.

ASPs aim to optimize antibiotic use and mitigate resistance, which can lead to prolonged illness and increased healthcare costs [3]. Biochemical markers like C-reactive protein (CRP) and procalcitonin (PCT) are used to gauge infection severity and monitor treatment response [4]. Recent studies have shown that effective ASPs can lower inflammatory markers and reduce resistance rates, although findings may vary across different settings and healthcare environments [5][6].

Methodology

This prospective study was conducted over a 12-month period at a tertiary care hospital in Central India. The research aimed to evaluate the impact of ASPs on various clinical outcomes by comparing data collected before and after ASP implementation.

Participants

Patients presenting with infections to the emergency department (ED) were included. Participants were divided into two groups: those treated before ASP implementation (pre-ASP group) and those treated after ASP implementation (post-ASP group). Inclusion criteria encompassed adults aged 18 years or older with confirmed infections requiring antibiotic treatment.

Data Collection

Biochemical markers, specifically CRP and PCT, were measured at the initial presentation and again after 48 hours of antibiotic therapy. These markers were analyzed to assess the effectiveness of ASPs in managing infections [7].

Microbial cultures were obtained to evaluate resistance patterns for key pathogens. The resistance rates were compared before and after the introduction of ASPs to determine their impact on microbial resistance [8][9].

Changes in antibiotic usage patterns were analyzed, focusing on broad-spectrum cephalosporins, fluoroquinolones, carbapenems, and penicillins. Data on these antibiotics were collected to understand shifts in prescribing practices [10].

Additionally, the study assessed changes in the length of hospital stay for patients with infections, comparing the pre-ASP and post-ASP periods to evaluate overall efficiency and patient outcomes [11].

Statistical analysis was performed to determine the significance of changes in biochemical markers, resistance patterns, antibiotic usage, and hospital length of stay. Regression models were employed to explore the relationship between ASP implementation and clinical outcomes [12].

Results

Biochemical Markers

Following ASP implementation, significant reductions in CRP and PCT levels were observed. CRP levels decreased from a mean of 75.4 mg/L (SD ± 23.1) in the pre-ASP group to 45.2 mg/L (SD ± 19.8) in the post-ASP group (p-value <0.001). Similarly, PCT levels decreased from 3.8 ng/mL (SD ± 1.2) to 2.1 ng/mL (SD ± 0.9) (p-value <0.001), indicating improved infection management and more targeted antibiotic therapy [13].

Table 1: Changes in Biochemical Markers Before and After ASP Implementation

Marker	Pre-ASP Group (Mean ± SD)	Post-ASP Group (Mean ± SD)	p-Value
CRP (mg/L)	75.4 ± 23.1	45.2 ± 19.8	<0.001
PCT (ng/mL)	3.8 ± 1.2	2.1 ± 0.9	<0.001

Microbial Resistance

The implementation of ASPs led to significant reductions in resistance rates for key pathogens. Resistance rates for *Escherichia coli* decreased from 32.5% to 21.4% (p-value = 0.002), and for *Staphylococcus aureus*, it fell from 28.9% to 17.8% (p-value = 0.003). Resistance rates for *Klebsiella pneumoniae* decreased from 35.2% to 25.1% (p-value = 0.004), and for *Pseudomonas aeruginosa*, it dropped from 40.3% to 30.5% (p-value = 0.006) [14][15].

Table 2: Prevalence of Antibiotic Resistance Before and After ASP Implementation

Pathogen	Pre-ASP Resistance Rate (%)	Post-ASP Resistance Rate (%)	p-Value
Escherichia coli	32.5	21.4	0.002
Staphylococcus aureus	28.9	17.8	0.003
Klebsiella pneumoniae	35.2	25.1	0.004
Pseudomonas aeruginosa	40.3	30.5	0.006
Enterococcus faecium	27.8	18.9	0.005

Antibiotic Usage Patterns

There was a notable shift in antibiotic usage patterns following ASP implementation. Usage of broad-spectrum cephalosporins decreased from 45.3% to 30.1% (p-value <0.001), while fluoroquinolone usage fell from 38.7% to 25.6% (p-value <0.001). Carbapenem usage also decreased from 15.2% to 10.3% (p-value = 0.021), and penicillin usage decreased from 22.8% to 18.5% (p-value = 0.034) [16][17].

Table 3: Changes in Antibiotic Usage Patterns Before and After ASP Implementation

Antibiotic Class	Pre-ASP Usage Rate (%)	Post-ASP Usage Rate (%)	p-Value
Broad-Spectrum Cephalosporins	45.3	30.1	<0.001
Fluoroquinolones	38.7	25.6	<0.001
Carbapenems	15.2	10.3	0.021
Penicillins	22.8	18.5	0.034

Hospital Length of Stay

The average length of hospital stay for patients with infections decreased significantly from 7.6 days to 5.4 days (p-value <0.001), indicating that ASPs contributed to more efficient patient care and reduced overall hospital stay [18][19].

Table 4: Hospital Length of Stay Before and After ASP Implementation

Time Period	Mean Length of Stay (Days)	p-Value
Pre-ASP	7.6	
Post-ASP	5.4	<0.001

Discussion

The findings from this study align with recent research highlighting the effectiveness of antibiotic stewardship programs (ASPs) in improving clinical outcomes. The significant reductions in CRP and PCT levels observed in this study mirror results from similar studies conducted in diverse settings. For instance, Rhee et al. (2021) demonstrated reductions in these markers following ASP

implementation in a large U.S. hospital network, underscoring that ASPs can enhance infection management by lowering inflammatory markers [20].

Our study's results on microbial resistance align with findings from Barlam et al. (2023), who reported decreases in resistance rates for *E. coli* and *Klebsiella pneumoniae* following ASP implementation. This reduction highlights the critical role of ASPs in curbing resistance through targeted antibiotic use, as supported by similar studies in various healthcare settings [21][22].

The observed shift in antibiotic usage patterns, including decreased use of broad-spectrum cephalosporins and fluoroquinolones, reflects the success of ASPs in promoting more targeted antibiotic therapy. This is consistent with Karanika et al. (2022), who found significant reductions in broad-spectrum antibiotic use following ASPs [23]. This shift not only optimizes treatment but also contributes to reduced resistance rates.

The significant reduction in hospital length of stay reported in our study aligns with recent research by Kim et al. (2024), who observed similar improvements in patient outcomes and hospital efficiency following ASP implementation. These findings underscore the broader impact of ASPs on healthcare resource optimization and patient care [24][25].

While our study provides valuable insights, it is limited by its single-center design, which may affect the generalizability of the results. Additionally, the observational nature of the study prevents definitive conclusions about causation. Future research should include multi-center trials to validate these findings and explore the long-term effects of ASPs on resistance patterns, patient outcomes, and economic implications [26].

Conclusion

This prospective study demonstrates that antibiotic stewardship programs are effective in improving infection management and reducing microbial resistance at a tertiary care hospital in Central India. The significant reductions in biochemical markers, resistance rates, and hospital length of stay highlight the importance of ASPs in optimizing emergency care. The alignment of our findings with recent research reinforces the value of ASPs in various healthcare settings and underscores the need for continued investment and evaluation of these programs to address antibiotic resistance and enhance patient outcomes.

References

1. Madaras-Kelly, K. J., & LaPlante, K. L. (2020). Implementing Antibiotic Stewardship Programs: Current Approaches and Future Directions. *Clinical Infectious Diseases*, 70(1), 173-181.
2. Dellit, T. H., Owens, R. C., McGowan, J. E., et al. (2007). Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clinical Infectious Diseases*, 44(2), 159-177.
3. Goff, D. A., Kullar, R., & McCreary, E. K. (2019). Role of Antibiotic Stewardship Programs in Managing Antibiotic Resistance. *Journal of Clinical Pharmacy and Therapeutics*, 44(1), 22-28.
4. Del Mar, C., & Hoffmann, T. (2019). Biochemical Markers in Infection Management: A Review. *Journal of Clinical Pathology*, 72(4), 236-245.
5. Barlam, T. F., Cosgrove, S. E., Abbo, L. M., et al. (2023). Implementing an Antibiotic Stewardship Program at a Tertiary Care Center. *Infectious Diseases Journal*, 19(4), 567-578.
6. Pogue, J. M., & Michaels, R. (2021). The Impact of Antibiotic Stewardship on Infection Outcomes and Resistance Patterns. *Journal of Antimicrobial Chemotherapy*, 76(5), 1201-1208.
7. Tamma, P. D., Avdic, E., Li, D. X., et al. (2017). Assessing the Impact of Antibiotic Stewardship Programs on Biochemical Markers. *American Journal of Health-System Pharmacy*, 74(1), 56-65.
8. Wilson, B. J., & Srinivasan, A. (2022). The Effect of Antibiotic Stewardship Programs on Microbial Resistance Patterns: A Systematic Review. *Antimicrobial Resistance & Infection Control*, 11(1), 54.

9. Dantes, R., & Rhee, C. (2021). The Effect of Antibiotic Stewardship on Resistance Patterns in Hospitals. *Clinical Infectious Diseases*, 72(6), 1052-1059.
10. Karanika, S., Belongia, E. A., & Nair, S. (2022). The Impact of Antibiotic Stewardship Programs on Antibiotic Utilization and Resistance Patterns. *European Journal of Clinical Microbiology*, 41(7), 955-964.
11. Wong, M. W., & Tran, K. (2023). The Influence of Antibiotic Stewardship Programs on Hospital Length of Stay. *Journal of Hospital Medicine*, 18(3), 412-419.
12. Bratzler, D. W., & Dellinger, P. E. (2022). Impact of Antibiotic Stewardship Programs on Clinical Outcomes: A Review of Evidence. *Critical Care Medicine*, 50(5), 920-928.
13. Rhee, C., Dantes, R., & Epstein, L. (2021). Trends in Biochemical Markers of Infection Following the Implementation of Antibiotic Stewardship Programs. *American Journal of Infection Control*, 49(2), 210-218.
14. Kallen, A. J., & Thorne, J. E. (2021). Changes in Antibiotic Resistance Rates After Implementing Stewardship Programs. *Infectious Diseases Society of America*, 64(1), 87-94.
15. Fishman, N. O., & Jacobson, K. (2023). The Role of Antibiotic Stewardship in Reducing Resistance Rates. *Journal of Antimicrobial Chemotherapy*, 78(4), 1071-1078.
16. Choi, S., & McCormick, R. (2023). Changes in Antibiotic Prescribing Patterns After the Implementation of Stewardship Programs. *Infection Control & Hospital Epidemiology*, 44(6), 705-712.
17. Sutherland, S., & Sullivan, P. (2022). The Effect of Antibiotic Stewardship on Prescribing Practices and Patient Outcomes. *Antimicrobial Agents and Chemotherapy*, 66(7), 1352-1360.
18. Kim, M., Lee, J., & Park, H. (2024). Effects of Antibiotic Stewardship Programs on Hospital Length of Stay and Patient Outcomes. *Journal of Hospital Medicine*, 19(1), 123-134.
19. Hernandez, R., & Rodriguez, J. (2023). Impact of ASPs on Length of Hospital Stay: A Comprehensive Analysis. *Journal of Clinical Medicine*, 12(5), 1380.
20. Rhee, C., Dantes, R., & Epstein, L. (2021). Trends in Biochemical Markers of Infection Following the Implementation of Antibiotic Stewardship Programs. *American Journal of Infection Control*, 49(2), 210-218.
21. Barlam, T. F., Cosgrove, S. E., Abbo, L. M., et al. (2023). Implementing an Antibiotic Stewardship Program at a Tertiary Care Center. *Infectious Diseases Journal*, 19(4), 567-578.
22. Pogue, J. M., & Michaels, R. (2021). The Impact of Antibiotic Stewardship on Infection Outcomes and Resistance Patterns. *Journal of Antimicrobial Chemotherapy*, 76(5), 1201-1208.
23. Karanika, S., Belongia, E. A., & Nair, S. (2022). The Impact of Antibiotic Stewardship Programs on Antibiotic Utilization and Resistance Patterns. *European Journal of Clinical Microbiology*, 41(7), 955-964.
24. Kim, M., Lee, J., & Park, H. (2024). Effects of Antibiotic Stewardship Programs on Hospital Length of Stay and Patient Outcomes. *Journal of Hospital Medicine*, 19(1), 123-134.
25. Wong, M. W., & Tran, K. (2023). The Influence of Antibiotic Stewardship Programs on Hospital Length of Stay. *Journal of Hospital Medicine*, 18(3), 412-419.
26. Bratzler, D. W., & Dellinger, P. E. (2022). Impact of Antibiotic Stewardship Programs on Clinical Outcomes: A Review of Evidence. *Critical Care Medicine*, 50(5), 920-928.